Single User License
INR 134980
Site License
INR 269960
Corporate User License
INR 404940

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Irritable Bowel Syndrome-Pipeline Review, H1 2015

Irritable Bowel Syndrome-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Irritable Bowel Syndrome-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Irritable Bowel Syndrome-Pipeline Review, H1 2015', provides an overview of the Irritable Bowel Syndrome's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Irritable Bowel Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Irritable Bowel Syndrome and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Irritable Bowel Syndrome

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Irritable Bowel Syndrome and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Irritable Bowel Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Irritable Bowel Syndrome pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Irritable Bowel Syndrome

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Irritable Bowel Syndrome pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Irritable Bowel Syndrome Overview 10

Therapeutics Development 11

Pipeline Products for Irritable Bowel Syndrome-Overview 11

Pipeline Products for Irritable Bowel Syndrome-Comparative Analysis 12

Irritable Bowel Syndrome-Therapeutics under Development by Companies 13

Irritable Bowel Syndrome-Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Irritable Bowel Syndrome-Products under Development by Companies 19

Irritable Bowel Syndrome-Companies Involved in Therapeutics Development 21

A. Menarini Industrie Farmaceutiche Riunite Srl 21

Actavis Plc 22

Alba Therapeutics Corporation 23

Alfa Wassermann S.p.A 24

Ardelyx, Inc. 25

Astellas Pharma Inc. 26

Dong-A Socio Group 27

GIcare Pharma Inc 28

Hanmi Pharmaceuticals, Co. Ltd. 29

ImmusanT, Inc. 30

Ironwood Pharmaceuticals, Inc. 31

Juno Therapeutics Inc. 32

Ono Pharmaceutical Co., Ltd. 33

Protagonist Therapeutics Inc. 34

RaQualia Pharma Inc. 35

SK Biopharmaceuticals Co., Ltd. 36

SK Chemicals Co., Ltd. 37

Sumitomo Dainippon Pharma Co., Ltd. 38

Synergy Pharmaceuticals, Inc. 39

Synthetic Biologics, Inc. 40

Takeda Pharmaceutical Company Limited 41

Yuhan Corporation 42

Irritable Bowel Syndrome-Therapeutics Assessment 43

Assessment by Monotherapy Products 43

Assessment by Combination Products 44

Assessment by Target 45

Assessment by Mechanism of Action 47

Assessment by Route of Administration 49

Assessment by Molecule Type 51

Drug Profiles 53

(Bacillus subtilis + mosapride + Streptococcus faecium)-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

ASP-1017-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

ASP-7147-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

Blautix-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

DA-6886-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

DSP-6952-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

eluxadoline-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

GIC-1001-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

ibodutant-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

larazotide acetate-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

linaclotide-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

Monoclonal Antibody to Antagonize M3 for Irritable Bowel Syndrome-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

Nexvax-2-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

ONO-2952-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

plecanatide-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

relenopride hydrochloride-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

rifaximin-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

RQ-00202730-Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

RQ-00310941-Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

SKI-3246-Drug Profile 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

Small Molecules to Inhibit 5-HT2B and 5-HT7 Receptors for IBS and Migraine-Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

Small Molecules to Inhibit SMURF2 for Fibrosis, Oncology and IBD-Drug Profile 80

Product Description 80

Mechanism of Action 80

R&D Progress 80

SYN-010-Drug Profile 81

Product Description 81

Mechanism of Action 81

R&D Progress 81

Synthetic Peptides for Gastrointestinal Disorders-Drug Profile 83

Product Description 83

Mechanism of Action 83

R&D Progress 83

Synthetic Peptides for Irritable Bowel Syndrome and Inflammatory Bowel Disease-Drug Profile 84

Product Description 84

Mechanism of Action 84

R&D Progress 84

TAK-480-Drug Profile 85

Product Description 85

Mechanism of Action 85

R&D Progress 85

tenapanor hydrochloride-Drug Profile 86

Product Description 86

Mechanism of Action 86

R&D Progress 86

YH-12852-Drug Profile 88

Product Description 88

Mechanism of Action 88

R&D Progress 88

Irritable Bowel Syndrome-Recent Pipeline Updates 89

Irritable Bowel Syndrome-Dormant Projects 109

Irritable Bowel Syndrome-Discontinued Products 113

Irritable Bowel Syndrome-Product Development Milestones 115

Featured News & Press Releases 115

May 27, 2015: Actavis Receives FDA Approval for VIBERZI (eluxadoline) for the Treatment of Irritable Bowel Syndrome with Diarrhea in Adults 115

May 20, 2015: 4D pharma Provides Research Update on Clinical Development Of Blautix 115

May 19, 2015: Ardelyx Presents Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients at Digestive Disease Week 2015 116

May 18, 2015: Synthetic Biologics' Novel SYN-010 Preclinical Data Featured in Digestive Disease Week Poster 117

Feb 17, 2015: Synthetic Biologics Announces Poster Presentation of C-IBS Candidate Therapy Data at Digestive Disease Week 2015 118

Jan 05, 2015: 4D pharma Provides Research Update 119

Dec 18, 2014: Synergy Pharmaceuticals Initiates First Phase 3 Clinical Trial of Plecanatide in Patients with Irritable Bowel Syndrome with Constipation 119

Nov 20, 2014: Ironwood Earns $15 Million Milestone from Astellas upon Initiation of Enrollment in Linaclotide Phase III IBS-C Clinical Trial in Japan 119

Nov 04, 2014: Ironwood Pharmaceuticals Initiates Phase III Trial of 72 mcg Linaclotide in Adult Patients with Chronic Idiopathic Constipation 120

Oct 21, 2014: Synergy Pharmaceuticals Presents Positive Phase 2b Study Results for Plecanatide in Patients with Irritable Bowel Syndrome with Constipation 120

Appendix 122

Methodology 122

Coverage 122

Secondary Research 122

Primary Research 122

Expert Panel Validation 122

Contact Us 122

Disclaimer 123

List of Tables

Number of Products under Development for Irritable Bowel Syndrome, H1 2015 11

Number of Products under Development for Irritable Bowel Syndrome-Comparative Analysis, H1 2015 12

Number of Products under Development by Companies, H1 2015 14

Number of Products under Development by Companies, H1 2015 (Contd..1) 15

Comparative Analysis by Late Stage Development, H1 2015 16

Comparative Analysis by Clinical Stage Development, H1 2015 17

Comparative Analysis by Early Stage Development, H1 2015 18

Products under Development by Companies, H1 2015 19

Products under Development by Companies, H1 2015 (Contd..1) 20

Irritable Bowel Syndrome-Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2015 21

Irritable Bowel Syndrome-Pipeline by Actavis Plc, H1 2015 22

Irritable Bowel Syndrome-Pipeline by Alba Therapeutics Corporation, H1 2015 23

Irritable Bowel Syndrome-Pipeline by Alfa Wassermann S.p.A, H1 2015 24

Irritable Bowel Syndrome-Pipeline by Ardelyx, Inc., H1 2015 25

Irritable Bowel Syndrome-Pipeline by Astellas Pharma Inc., H1 2015 26

Irritable Bowel Syndrome-Pipeline by Dong-A Socio Group, H1 2015 27

Irritable Bowel Syndrome-Pipeline by GIcare Pharma Inc, H1 2015 28

Irritable Bowel Syndrome-Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2015 29

Irritable Bowel Syndrome-Pipeline by ImmusanT, Inc., H1 2015 30

Irritable Bowel Syndrome-Pipeline by Ironwood Pharmaceuticals, Inc., H1 2015 31

Irritable Bowel Syndrome-Pipeline by Juno Therapeutics Inc., H1 2015 32

Irritable Bowel Syndrome-Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 33

Irritable Bowel Syndrome-Pipeline by Protagonist Therapeutics Inc., H1 2015 34

Irritable Bowel Syndrome-Pipeline by RaQualia Pharma Inc., H1 2015 35

Irritable Bowel Syndrome-Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2015 36

Irritable Bowel Syndrome-Pipeline by SK Chemicals Co., Ltd., H1 2015 37

Irritable Bowel Syndrome-Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015 38

Irritable Bowel Syndrome-Pipeline by Synergy Pharmaceuticals, Inc., H1 2015 39

Irritable Bowel Syndrome-Pipeline by Synthetic Biologics, Inc., H1 2015 40

Irritable Bowel Syndrome-Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 41

Irritable Bowel Syndrome-Pipeline by Yuhan Corporation, H1 2015 42

Assessment by Monotherapy Products, H1 2015 43

Assessment by Combination Products, H1 2015 44

Number of Products by Stage and Target, H1 2015 46

Number of Products by Stage and Mechanism of Action, H1 2015 48

Number of Products by Stage and Route of Administration, H1 2015 50

Number of Products by Stage and Molecule Type, H1 2015 52

Irritable Bowel Syndrome Therapeutics-Recent Pipeline Updates, H1 2015 89

Irritable Bowel Syndrome-Dormant Projects, H1 2015 109

Irritable Bowel Syndrome-Dormant Projects (Contd..1), H1 2015 110

Irritable Bowel Syndrome-Dormant Projects (Contd..2), H1 2015 111

Irritable Bowel Syndrome-Dormant Projects (Contd..3), H1 2015 112

Irritable Bowel Syndrome-Discontinued Products, H1 2015 113

Irritable Bowel Syndrome-Discontinued Products (Contd..1), H1 2015 114

List of Figures

Number of Products under Development for Irritable Bowel Syndrome, H1 2015 11

Number of Products under Development for Irritable Bowel Syndrome-Comparative Analysis, H1 2015 12

Number of Products under Development by Companies, H1 2015 13

Comparative Analysis by Clinical Stage Development, H1 2015 17

Comparative Analysis by Early Stage Products, H1 2015 18

Assessment by Monotherapy Products, H1 2015 43

Number of Products by Top 10 Targets, H1 2015 45

Number of Products by Stage and Top 10 Targets, H1 2015 45

Number of Products by Top 10 Mechanism of Actions, H1 2015 47

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 47

Number of Products by Top 10 Routes of Administration, H1 2015 49

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 49

Number of Products by Top 10 Molecule Types, H1 2015 51

Number of Products by Stage and Top 10 Molecule Types, H1 2015 51

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

A. Menarini Industrie Farmaceutiche Riunite Srl

Actavis Plc

Alba Therapeutics Corporation

Alfa Wassermann S.p.A

Ardelyx, Inc.

Astellas Pharma Inc.

Dong-A Socio Group

GIcare Pharma Inc

Hanmi Pharmaceuticals, Co. Ltd.

ImmusanT, Inc.

Ironwood Pharmaceuticals, Inc.

Juno Therapeutics Inc.

Ono Pharmaceutical Co., Ltd.

Protagonist Therapeutics Inc.

RaQualia Pharma Inc.

SK Biopharmaceuticals Co., Ltd.

SK Chemicals Co., Ltd.

Sumitomo Dainippon Pharma Co., Ltd.

Synergy Pharmaceuticals, Inc.

Synthetic Biologics, Inc.

Takeda Pharmaceutical Company Limited

Yuhan Corporation

Irritable Bowel Syndrome Therapeutic Products under Development, Key Players in Irritable Bowel Syndrome Therapeutics, Irritable Bowel Syndrome Pipeline Overview, Irritable Bowel Syndrome Pipeline, Irritable Bowel Syndrome Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com